ArticleCancers2021

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.

Valérie Gounant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.